Page 1

isoray BEYOND YOUR CANCER Exhibit 99.1 Isoray Announces First Quarter Fiscal 2022 Financial Results Prostate Revenue Increased Year - Over - Year for Second Consecutive Quarter Non - Prostate Brachytherapy Revenue Increased 20 % Year - Over - Year RICHLAND , Wash . , Nov. 10 , 2021 ( GLOBE NEWSWIRE ) -- Isoray , Inc. ( NYSE AMERICAN : ISR ) , a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body , today announced its financial results for the first quarter fiscal 2022 ended September 30 , 2021 . Revenue for the first quarter of fiscal 2022 grew 8 % to $ 2.56 million versus $ 2.38 million in the prior year comparable period . The company's core prostate brachytherapy revenue increased 4 % versus the first quarter of fiscal 2021. Prostate brachytherapy represented 77 % of total revenue for the first quarter of fiscal 2022 compared to 79 % in the prior year comparable period . Non - prostate brachytherapy revenue increased 20 % versus the prior year comparable period . The majority of non - prostate brachytherapy revenue in the quarter was comprised of sales to treat brain cancer , including sales of GammaTile® Therapy . Gross profit as a percentage of revenues was 40.1 % for the three months ended September 30 , 2021 versus 52.3 % in the prior year comparable period . First quarter gross profit decreased 17 % to $ 1.03 million versus $ 1.25 million in the first quarter of fiscal 2021 , as the year over year sales growth was offset by increased costs of goods sold primarily as the result of greater isotope and non - isotope material costs as well as increased payroll and benefits expense due to the increase in headcount versus the prior year comparable period . Isoray CEO Lori Woods said , " We are encouraged by the prospects for our core prostate brachytherapy business which grew year over year again this quarter . As our innovation pipeline continues to evolve , we are taking what we believe are important steps critical to support the scaling of the organization in anticipation of future growth in our core prostate brachytherapy market as well as in markets related to hard - to - treat cancers . " Total operating expenses increased 69 % in the first quarter to $ 3.30 million from $ 1.96 million in the prior year period . Total research and development expenses increased 125 % versus the prior year comparable period . The increase in research and development expenses was primarily the result of increased payroll and benefits expense due to greater headcount , increased share - based stock compensation expense due to a timing shift in annual employee stock grants , and higher market research expenses versus the prior year comparable period . Sales and marketing expenses increased 31 % versus the prior year comparable period . The increase in sales and marketing expenses was driven primarily by increases in travel and tradeshow costs and increased share - based stock compensation expense due to a timing shift in annual employee stock grants versus the prior year comparable period . General and administrative expenses increased 72 % versus the prior year comparable period . The increases in general and administrative expenses were primarily the result of increased payroll and benefits expense due to annual merit increases and greater headcount , increased employment hiring expenses , and increased share - based stock compensation expense due to a timing shift in annual employee and director stock grants versus the prior year comparable period . The net loss for the three months ended September 30 , 2021 was $ 2.24 million or ( $ 0.02 ) per basic and diluted share versus a net loss of $ 0.71 million or ( $ 0.01 ) per basic and diluted share in the comparable prior year period . Basic and diluted per share results are based on weighted average shares outstanding of approximately 141.9 million for the three months ended September 30 , 2021 versus 68.9 million in the comparable prior year period . Cash , cash equivalents , and certificates of deposit at the end of the first quarter of fiscal 2022 totaled $ 61.7 million and the company had no debt . Stockholders ' equity at the end of the first quarter of fiscal 2022 totaled $ 65.8 million .